<DOC>
	<DOCNO>NCT00347100</DOCNO>
	<brief_summary>Primary : - To investigate efficacy insulin glargine ( term change A1c baseline endpoint A1c &lt; 7 % ) Secondary : - To investigate safety insulin glargine ( term hypoglycaemia , include symptomatic , non-symptomatic nocturnal hypoglycaemia ) - To investigate whether beta cell function preserve therapy initiate 2nd OAD ( oral anti-diabetic drug ) failure</brief_summary>
	<brief_title>Insulin Glargine Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Type 2 diabetes patient first OAD ( Sulfonylurea [ SU ] Metformin ) failure Patients insulin naive ( unless use gestational diabetes insulin therapy le 1 week ) Serum creatinine ≤ 1.5mg/dL BMI : 2141 kg/m² 7.5 % &lt; A1c &lt; 11 % Fasting plasma glucose &gt; 7.5mmol/L On diet exercise therapy stable OAD treatment ( SU metformin &gt; ½ maximal dose ) 1 month prior enrolment Women childbearing potential ( sterilization procedure do menopausal &gt; 2 year ) , childbearing potential , agree take reliable contraceptive measure study Able willing monitor blood glucose Able willing perform 7 point blood glucose self monitoring baseline , 12 week 24 week Understand 50 % chance randomize insulin treatment arm willing self inject insulin Type 1 diabetes Acute complication diabetes , diabetic ketoacidosis hyperosmolar coma Pregnancy , breastfeed People work night shift Hypersensitivity investigational drug additive , intolerability metformin Need use medication prohibit protocol study treatment purpose Significant diseases cardiovascular , liver , nerve , endocrine system , unable complete study difficult use study analysis Drugs alcohol abuse The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>